- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01353066
Gastric Bypass Versus Best Medical Treatment on Progression of Carotid-intima Media Thickness in Type 2 Diabetes Mellitus (T2DM) (EURDSS)
Multicenter Randomized Prospective Trial on the Effects of Intensive Medical Treatment of Type 2 Diabetes With and Without Roux-in-Y Gastric Bypass Surgery on Carotid Intima Media Thickness in Grade I Obesity (BMI 30,0-34,9 kg/m2)
Background: Type 2 Diabetes Mellitus (T2DM) is associated with an increased burden for cardiovascular disease (CVD). Multifactorial interventions are necessary to reduce the CV risk in T2DM. Bariatric surgery appears to be an alternative for the multifactorial intervention in T2DM associated with obesity. Data have shown, that clinical trial aiming at the control of CVRF in T2DM may not translate in the reduction of CV events.
Hypothesis: Intensive medical treatment (IMM) including Roux-en-Y Gastric Bypass (RYGBP) could be superior in the control of the progression of subclinical atherosclerotic disease, as evaluated by carotid ultrasound, in subjects with T2DM and a BMI between 30.0 and 34.9 kg/m2.The primary aim of the study is To compare the effects of intensive medical treatment (IMM) including Roux-en-Y Gastric Bypass (RYGBP) and IMM alone on the progression of the carotid intima media thickness (CIMT) at 24 months after entry into the trial relative to baseline.Methodology: Two-year Randomized Clinical Trial, including 240 patients
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Catalunya
-
Barcelona, Catalunya, Spanien, 08036
- Hospital Clinic de Barcelona
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 35 to 65 years at eligibility visit.
- Diagnosed with T2DM at least 6 months prior to enrollment, under the active care of a doctor for at least he six months prior to enrollment, and HbA 1c > 7.0 %.
- Current treatment for T2DM consisting of multiple doses of insulin with/without hypoglycemic agents or hypoglycemic agents plus basal insulin.
- Optimization of diabetes medical treatment prior to inclusion in the study would have been performed based on best medical practices.
- Body Mass Index (BMI)> 30.0 kg/m2 and <34.9 kg/m2 at eligibility visit.
- Willingness to accept random assignment to either treatment group.
- Expect to live or work within approximately one hour's traveling time from the study clinic for the duration of the two-year trial.
- Willingness to comply with the follow-up protocol and successful completion of the run-in.
- Written informed consent.
Exclusion Criteria:
- Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months.
- Current evidence of congestive heart failure (grade II or IV), angina pectoris, symptomatic peripheral vascular disease or advanced cardiovascular disease.
- History of severe hypoglycemic episodes associated with medical treatment of type 2 DM
- Cardiac stress test indicating that surgery would not be safe
- Pulmonary embolus or thrombophlebitis in the past six months.
- Cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented to be disease-free for five years.
- Significant anemia or history of coagulopathy.
- Serum creatinine >1.5 mg/dl.
- Serum total bilirubin or alkaline phosphatase greater than the upper limit of normal, or ALT greater than twice the upper limit of normal.
- History of previous surgery contraindicating gastric bypass at the criteria of the surgical team.
- Gastric or duodenal ulcer in the past six months.
- History of intra-abdominal sepsis (except for uncomplicated appendicitis or diverticulitis more than six months prior to enrollment).
- Previous organ transplantation.
- Self-reported HIV-positive status, active tuberculosis, active malaria, chronic hepatitis B or C, cirrhosis, or inflammatory bowel disease.
- Currently pregnant or nursing, or planning to become pregnant in the next two years.
- History of alcohol or drug dependency (excluding caffeine and nicotine) in the past five years
- Active psychosocial or psychiatric problem that is likely to interferer with adherence to the protocol.
- Score of 17 or higher on the CES-D (depression scale).
- Current participation in a conflicting research protocol.
- Presence of any chronic or debilitating disease that would make adherence to the protocol difficult.
- 12-lead EKG indicating that surgery or intensive medical treatment would not be safe.
- Diagnosed with diabetes more than 15 years ago.
- Positive GAD antibodies
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Intensive Medical Treatment
|
|
|
Eksperimentel: Intensive medical treatment (IMM)+RYGBP
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Measurement of the progression carotid intima media thickness (CIMT) at 24 months after entry into the trial relative to baseline
Tidsramme: 24 months
|
24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HCB-UOM-012011
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Aterosklerotisk kardiovaskulær sygdom
-
Ottawa Hospital Research InstituteAfsluttetStress | Crisis Resource Management (CRM) færdigheder | Advanced Cardiovascular Life Support (ACLS) færdighederCanada
Kliniske forsøg med Intensive Medical Treatment
-
Ospedale Generale Di Zona Moriggia-PelasciniAfsluttetParkinsons sygdom og Pisa syndromItalien
-
Stanford UniversityJohn & Marcia Goldman FoundationAfsluttetAutismespektrumforstyrrelse | AutismeForenede Stater
-
Nova Scotia Health AuthorityAfsluttetSomatiske symptomer og relaterede lidelser | Intensiv kortvarig dynamisk psykoterapiCanada
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)RekrutteringAutismespektrumforstyrrelse | AutismeForenede Stater
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) og andre samarbejdspartnereAfsluttet
-
Universidad Católica San Antonio de MurciaAfsluttetRygsmerte | Atletiske skader | Rygspænding Nedre rygSpanien
-
Stanford UniversityAfsluttetAutismespektrumforstyrrelseForenede Stater
-
Virginia Polytechnic Institute and State UniversityAfsluttetAutismespektrumforstyrrelseForenede Stater
-
Uşak UniversityAfsluttetLivskvalitet | Overholdelse af behandlingKalkun
-
The Cleveland ClinicTwin HealthAktiv, ikke rekrutterende